文献类型：期刊文献

英文题名：Application of nanoparticles in drug delivery for the treatment of osteosarcoma: focussing on the liposomes

作者：Liang, Wenqing[1];Dong, Yongqiang[2];Shao, Ruyi[3];Zhang, Songou[4];Wu, Xudong[1];Huang, Xiaogang[1];Sun, Bin[1];Zeng, Bin[1];Zhao, Jiayi[1]

机构：[1]Zhejiang Chinese Med Univ, Zhoushan Hosp Tradit Chinese Med, Dept Orthoped, 355 Xinqiao Rd, Zhoushan 316000, Peoples R China;[2]Xinchang Peoples Hosp, Dept Orthoped, Shaoxing, Peoples R China;[3]Zhuji Peoples Hosp, Dept Orthoped, Shaoxing, Peoples R China;[4]Shaoxing Univ, Coll Med, Shaoxing, Peoples R China

年份：2022

卷号：30

期号：5

起止页码：463

外文期刊名：JOURNAL OF DRUG TARGETING

收录：SCI-EXPANDED(收录号：WOS:000739188500001)、、Scopus(收录号：2-s2.0-85122315017)、WOS

基金：This work was supported by Nature Science Foundation of Zhejiang Province [Grant number LGF22H060023], Medical and Health Research Project of Zhejiang Province [Grant numbers 2020KY995 and 2021KY1172], Science and Technology Project of Shaoxing [Grant numbers 2018C30165 and 2018C30149], and Science and Technology Project of Zhoushan [Grant number 2021C31099].

语种：英文

外文关键词：Osteosarcoma; nanomaterial; drug delivery system; nanocarrier; liposome

外文摘要：Osteosarcoma (OS) is one of the most common primary bone malignancies in children and adolescents. The toxicity to healthy tissues from conventional therapeutic strategies, including chemotherapy and radiotherapy, and drug resistance, severely affects OS patients' quality of life and cancer-specific outcomes. Many efforts have been made to develop various nanomaterial-based drug delivery systems with specific properties to overcome these limitations. Among the developed nanocarriers, liposomes are the most successful and promising candidates for providing targeted tumour therapy and enhancing the safety and therapeutic effect of encapsulated agents. Liposomes have low immunogenicity, high biocompatibility, prolonged half-life, active group protection, cell-like membrane structure, safety and effectiveness. This review will discuss various nanomaterial-based carriers in cancer therapy and then the characteristics and design of liposomes with a particular focus on the targeting feature. We will also summarise the recent advances in the liposomal drug delivery system for OS treatment in preclinical and clinical studies.